Torrent Pharma Reports Strong Q3 on USFDA Clearance and Sales

The USFDA inspected Torrent Pharma's Bileshwarpura (Oncology) facility in Gujarat from April 6 to April 10, 2026. The inspection concluded with zero observations, indicating the facility meets stringent global standards for drug manufacturing. This clearance is vital for the company's access to the key US market.

USFDA Facility Cleared

This regulatory success comes as the company also reported strong financial results for Q3 FY26. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) increased by 19% to ₹1,088 crore, with margins steady at 32.9%. The USFDA clearance is especially important for continued market access in the United States, a significant contributor to Torrent's revenue, particularly amid heightened industry regulatory oversight.

Key Markets Drive Revenue Growth

The company also outperformed in key markets. Indian revenues grew 14% to ₹1,798 crore, exceeding the broader Indian Pharmaceutical Market (IPM) growth of 10%. Strong performance in cardiac, gastro, and diabetes therapies drove this success. Brazil was another highlight, with revenues surging 27% to ₹371 crore, far ahead of the market's 7% growth. The US business added 19% in revenue, reaching ₹321 crore, with new products achieving their market share goals.

Valuation vs. Peers

Torrent Pharma's market capitalization is around ₹1.40 lakh crore. Its P/E ratio of 60x-72x is higher than many Indian peers like Lupin (22.7x) and Dr. Reddy's Laboratories (17.6x), and also Sun Pharma (high 30s) and Cipla (low 40s). This premium valuation suggests strong investor expectations for growth and regulatory adherence. Historically, the stock has reacted positively to clean USFDA inspections; for example, shares rose 4% after a VAI classification in August 2024.

Challenges Ahead: Competition and Costs

Despite strong performance, the sector faces challenges. Sustained pricing pressure in the U.S. generics market and rising costs for raw materials can impact profitability, even for companies with significant U.S. operations like Torrent. The company's premium valuation means it must continue to deliver consistent growth and regulatory compliance. Any regulatory misstep or a sharp change in U.S. pricing could affect its market position.

Analyst View and Future Projections

Analysts forecast continued growth for Torrent Pharma, projecting annual earnings increases of around 21.3% and revenue growth of 24.3%. The consensus rating for the stock is 'BUY,' with an average 1-year price target near ₹4,527. Recent analyst target price hikes reflect optimism about the company's strategy and growth potential. Torrent Pharma is scheduled to report its next earnings on May 21, 2026.